# A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors

Source: https://onco.cc/trials/nct06437522/  
OnCo record `nct06437522` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Izalontamab brengitecan in head and neck squamous cell carcinoma, run by Sichuan Baili Pharmaceutical Co., Ltd., now recruiting.

## Summary

A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors is a phase 2 interventional study registered as NCT06437522 by Sichuan Baili Pharmaceutical Co., Ltd., with 46 participants planned, started 2024-06-07 and due to reach its primary completion in 2027-06. Interventions recorded: BL-B01D1, PD-1 monoclonal antibody. Conditions listed: Head and Neck Squamous Cell Carcinoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06437522
- Phase: 2
- Setting: A Phase II Clinical Trial To Evaluate the Efficacy and Safety of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (Non-nasopharyngeal Carcinoma) and Other Solid Tumors
- Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
- Enrolled: 46

## Sources

- ClinicalTrials.gov NCT06437522: https://clinicaltrials.gov/study/NCT06437522

## Connected records

- cancers: [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/)
- drugs: [Izalontamab brengitecan](https://onco.cc/drugs/izalontamab-brengitecan/)
- companies: [SystImmune / Sichuan Biokin](https://onco.cc/companies/systimmune/)

---
JSON: https://onco.cc/api/v1/entities/nct06437522.json